# Neurofilament light chain and glial fibrillary acidic protein as biomarkers of peripheral nervous system involvement in multiple sclerosis: diagnostic and prognostic evaluation.

- **DOI:** [10.1186/s12883-026-05024-y](https://doi.org/10.1186/s12883-026-05024-y)
- **Rating:** Limited (2.7 out of 5)
- **Verdict:** A useful cross-sectional biomarker study confirms higher NfL in MS, but unsupported diagnostic and prognostic framing obscures its limited PNP-specific advance.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1186%2Fs12883-026-05024-y

## Key claims

1. Serum NfL was found to be a reliable marker of disease activity and progression.
   - Support: Tentative
   - Type: Primary finding
   - Basis: cross-sectional comparisons cannot establish monitoring reliability or progression prediction
   - Location: Abstract, Results
2. The presence of co-existing polyneuropathy influenced biomarker levels and complicated their interpretation.
   - Support: Tentative
   - Type: Secondary
   - Basis: the small cross-sectional PNP subgroup showed no independent adjusted NfL effect
   - Location: Abstract, Results
3. GFAP demonstrated limited specificity and was not suitable as a single, independent biomarker.
   - Support: Tentative
   - Type: Secondary
   - Basis: group differences were tested, but diagnostic specificity and independent performance were not evaluated
   - Location: Abstract, Results
4. serum NfL levels were significantly higher in patients with MS compared to healthy controls
   - Support: Supported
   - Type: Secondary
   - Basis: adjusted group comparisons support the direction despite baseline-reporting and cross-sectional limitations
   - Location: Discussion, paragraph 3; Table 2
5. differences between MS patients with and without PNP were attenuated after adjustment for age and sex
   - Support: Supported
   - Type: Secondary
   - Basis: Table 2 directly reports near-elimination of the contrast after adjustment, though residual confounding remains
   - Location: Discussion, paragraph 3; Table 2

## Strengths

- **Standardised electrophysiological PNP classification** All patients underwent a standardised NCS protocol, and large-fibre PNP required abnormalities in multiple parameters across at least two nerves. This gives the subgroup comparison a clinically grounded phenotype.
  - Dimension: methodological rigour
  - Location: Methods, Clinical Assessment and Group Classification
- **Blinded single-batch biomarker measurement** NfL and GFAP were measured using Simoa in one batch by technicians blinded to clinical data, with intra-assay coefficients of variation below 10%.
  - Dimension: methodological rigour
  - Location: Methods, Blood Sampling and Biomarker Analysis
- **Limitations linked to interpretation** The Discussion and Limitations address treatment confounding, absent age-adjusted Z-scores, mixed PNP aetiology, random sampling relative to relapse, and the need for an isolated-PNP comparator.
  - Dimension: positioning
  - Location: Discussion, treatment paragraph; Limitations

## Limitations

- **Baseline age statistics appear inconsistent** The MS-with-PNP group is approximately 10 years older than the MS-without-PNP group, yet the Results report p > 0.05. Because age is strongly associated with NfL in Table 2, this inconsistency bears directly on the central adjusted comparison.
  - Dimension: methodological rigour
  - Location: Results, paragraph 1; Table 2
- **Abstract overstates clinical validation** The Abstract calls NfL reliable for activity and progression and attributes an effect to PNP, although the Introduction disclaims prognostic testing and the adjusted PNP comparison is p = 0.951.
  - Dimension: reporting
  - Location: Abstract, Results and Conclusion; Introduction, final paragraph; Table 2
- **Novel PNP comparison remains unresolved** Only 24 MS patients had PNP, and the adjusted difference from MS without PNP was 0.06 with p = 0.951. The study therefore does not demonstrate an independent PNP effect on NfL.
  - Dimension: contribution
  - Location: Results, Table 2; Discussion, paragraph 3

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - The presence of co-existing polyneuropathy influenced biomarker levels and complicated their interpretation: "The presence of co-existing polyneuropathy influenced biomarker levels and complicated their interpretation." (Abstract, Results) vs "MS with PNP – MS without PNP0.06-1.91–2.440.951" (Table 2, model with covariates). Compare the Abstract's affirmative PNP-effect statement with the adjusted within-MS NfL contrast, which is 0.06 pg/mL with a 95% CI of −1.91 to 2.44 and p = 0.951; the Results also report no significant GFAP group differences. → Not supported by the paper's own data
  - differences between MS patients with and without PNP were attenuated after adjustment for age and sex: "The mean age was 41.5 ± 11.1 years in the control group, 50.3 ± 8.1 years in the MS with PNP group, and 40.6 ± 11.2 years in the MS without PNP group (p > 0.05)." (Results, first paragraph) vs "The sex distribution was as follows: control group (11 male, 29 female), MS with PNP group (13 male, 11 female), and MS without PNP group (41 male, 84 female)." (Results, first paragraph). Using group sizes 24 and 125 from the sex counts and treating the rounded age summaries as inputs, an assumed two-sided Welch comparison gives t ≈ 5.02, df ≈ 41.94 and p ≈ 0.00001, challenging baseline age comparability but not changing the separately reported adjusted PNP contrast. → Conclusion holds
- **Reporting and transparency:** Noted. Correlation analyses described in Methods are not presented, leaving the conclusion's disability association uncheckable. The descriptive biomarker summaries also mix mean and median labels.
  - Conflict of interest: not stated · Ethics approval: declared · Preregistration: not stated · Data availability: not stated · Code availability: not stated
- **Reference integrity:** Clean
  - 22 references in manuscript
  - 22 of 22 checkable references found in an index
  - 1 DOI is not registered:
    - #1 Fabian MT, Krieger SC, Lublin FD. Multiple Sclerosis and Other Inflammatory Demyelinating Diseases of the Central Nervous System. In: Bradley and Daroff's Neurology in Clinical Practice: Volume 1-2. 8th ed. Elsevier; 2021. Vol. 2. pp. 1226-54.e5). 10.1016/B978-0-323-64261-3.00080-2. (Not registered with any DOI agency — the link below does not resolve) https://doi.org/10.1016/B978-0-323-64261-3.00080-2
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
